#USA #New York #Joseph Levi #VYKAT XR #Soleno Therapeutics

Investor Alert: Soleno Therapeutics and the Class Action Lawsuit

Introduction

On April 1, 2026, Levi & Korsinsky, LLP announced aclass action lawsuit concerning Soleno Therapeutics, Inc. (NASDAQ: SLNO). This legal action aims to address significant consumer grievances stemming from potential misconduct during clinical trials related to their sole commercial product, DCCR (marketed as VYKAT XR), used to treat hyperphagia in patients with Prader-Willi syndrome. Following a period when Soleno’s stock was bought and sold, a plethora of investors have found themselves in a precarious situation after the company’s alleged misrepresentation of crucial clinical trial data.

Background of Soleno Therapeutics

Soleno Therapeutics specializes in treatments for rare disorders. DCCR received FDA approval after a pivotal Phase 3 clinical trial program, prominently featuring a randomized withdrawal study that served as the backbone of Soleno’s claims regarding the drug's efficacy and safety. However, with the lawsuit now in motion, questions surrounding the integrity of this data could jeopardize both the pharmaceutical's credibility and its financial future.

Overview of the Lawsuit

The class action lawsuit focuses on investor claims from those who purchased Soleno securities between March 26, 2025, and November 4, 2025. As per Levi & Korsinsky, the legal battle comes on the heels of disclosed systematic issues within Soleno’s clinical trials that could compromise the entire safety framework supporting DCCR.

Key Allegations

• - Pivotal Study Concerns: The well-being of DCCR is now under scrutiny due to reports indicating only 77 individuals were enrolled in the pivotal randomized withdrawal study—numbers that raise flags in the research community regarding the reliability of its conclusions. Furthermore, many trials reportedly displayed bias and a lack of comprehensive methodology.
• - Lack of Efficacy: The initial 13-week Phase 3 trial failed to hit its primary endpoint, highlighting an alarming trend where the anticipated improvements in hyperphagia were not observed. The analysis suggests that investigators discovered placebo effects hampering accurate data collection due to visible side effects.
• - Doubts from Experts: Credibility is further damaged with commentary from various endocrinologists and independent research firms. Many experts have expressed disbelief regarding the safety and efficacy of DCCR, detracting from investor confidence and potentially endangering public health.

Safety Issues: Fluid Retention and Visibility

Among the more concerning issues reported are complications related to the treatment’s mechanism—specifically fluid retention—which is a known side effect of diazoxide. Allegedly, clinical events resembling pulmonary edema and potential heart failure emerged during the trials, but these serious risks were downplayed in company communications. Given that these complications become more pronounced over time, the lawsuit claims that Soleno failed to provide transparent insights to investors regarding DCCR’s long-term safety profile.

Conclusion and Future Implications

As the deadline for investors to seek lead plaintiff status approaches on May 5, 2026, the consequences of this lawsuit could have extensive ramifications for Soleno Therapeutics, its stakeholders, and potentially, broader patient safety. Investor confidence remains shaky while concerns about clinical misconduct and ethics linger in the healthcare narrative surrounding Soleno. Investors are urged to consider their options carefully and to connect with legal counsel, as they may be entitled to recover losses without incurring out-of-pocket fees. As this case continues to unfold, it serves as a significant reminder of the intersection between ethics, pharmaceutical innovation, and investor protection.

For further inquiries, interested parties can reach out to Joseph E. Levi, Esq. or the firm directly at (212) 363-7500.